EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controls Mycobacterium tuberculosis in mice

Hilliard L Kutscher iD, Maria Tamblin, Evon Smith, Arnav Shah, Patrick O Kenney iD, Jessica L Reynolds iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01480-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Hilliard L Kutscher und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical and Translational Research Center, The State University of New Yor…. Hauptthemen laut MEDLINE: Chitosan, Rifampin, Nanoparticles, beta-Glucans. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To address limitations in tuberculosis (TB) therapy, we developed an inhalable, immunomodulating, biocompatible nanoparticle system (β-C-P) encapsulating rifampin that targets alveolar macrophage. The nanoparticle consists of a poly(lactic-co-glycolic acid) (PLGA) core, a chitosan coating, and a surface functionalized with 1,3-β-glucan for enhanced macrophage uptake and immunomodulation. We evaluated the safety, immunological effects, and efficacy of rifampin-loaded β-C-P nanoparticles delivered via oropharyngeal aspiration (OPA) in healthy mice and in a low-dose Mycobacterium tuberculosis (Mtb ) BALB/c model treated weekly for 4 weeks, as well as in a low-dose Mtb C3HeB/FeJ model treated weekly for 8 weeks. In healthy mice, cell pellets isolated by bronchoalveolar lavage (BAL) showed higher pulmonary exposure (AUC) of rifampin with 20% β-C-P nanoparticles versus 5% β-C-P nanoparticles, while no rifampin was detected in the oral rifampin group. Flow cytometry revealed no significant changes in lung immune cell populations except for a transient neutrophil increase at day 21 in the 5% β-C-P group. In the Mtb BALB/c mouse model, weekly OPA administration of 5%, 10%, and 20% β-C-P nanoparticles significantly reduced lung CFU by 0.5–1.11 log 10 , comparable to daily oral rifampin. In the Mtb C3HeB/FeJ (Kramnik) mouse model, weekly OPA administration of 10% and 20% β-C-P nanoparticles significantly reduced lung CFU, comparable to daily oral rifampin. Collectively, these findings demonstrate that weekly pulmonary nanoparticle delivery of rifampin-loaded β-C-P nanoparticles achieves sustained rifampin exposure and therapeutic efficacy comparable to daily dosing, without pulmonary toxicity or systemic immune activation. This supports the potential of long-acting inhalable formulations for simplified TB therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChitosanRifampinNanoparticlesbeta-GlucansMycobacterium tuberculosisLactic AcidPolyglycolic AcidAnimalsPolylactic Acid-Polyglycolic Acid CopolymerMiceMice, Inbred BALB CLungFemaleBronchoalveolar Lavage Fluid

Stichwörter der Autor:innen

Mycobacterium tuberculosisPLGAbeta glucanimmune profilingnanoparticlesrifampin

Substanzen

ChitosanPolylactic Acid-Polyglycolic Acid CopolymerRifampinbeta-GlucansLactic AcidPolyglycolic Acid

Autor:innen und Institutionen

  • Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical and Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
  • Institute for Lasers, Photonics and Biophotonics, The State University of New York at Buffalo, Buffalo, New York, USA.
  • Department of Anesthesiology, The State University of New York at Buffalo, Buffalo, New York, USA.
  • Adult and Pediatric Infectious Disease, The State University of New York at Buffalo, Buffalo, New York, USA.

ORCID-Profile: Hilliard L Kutscher, Patrick O Kenney, Jessica L Reynolds

Förderung

  • NIAID NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Kutscher, H. L., Tamblin, M., Smith, E., Shah, A., Kenney, P. O., & Reynolds, J. L. (2026). Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controls Mycobacterium tuberculosis in mice. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01480-25

Vancouver

Kutscher HL, Tamblin M, Smith E, Shah A, Kenney PO, Reynolds JL. Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controls Mycobacterium tuberculosis in mice. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01480-25

BibTeX
@article{Kutscher2026,
  author = {Kutscher, Hilliard L and Tamblin, Maria and Smith, Evon and Shah, Arnav and Kenney, Patrick O and Reynolds, Jessica L},
  title = {Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controls Mycobacterium tuberculosis in mice},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01480-25}
}
Kostenlos starten →